Targeting PI3K signaling as a therapeutic approach for colorectal cancer

Gastroenterology

Volumn 141, Issue 1, 2011, Pages 50-61

  Zhang, Jing ^a   Roberts, Thomas M ^a   Shivdasani, Ramesh A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Colon Cancer; Genetics; Neoplasm; Signal Transduction; Tumor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; AZD 8055; BKM 120; BYL 719; CAL 101; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 2206; NVP BGT 226; NVPBGT 226; OSI 027; PD 89059; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOINOSITIDE 3 KINASE CATALYTIC ALPHA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B INHIBITOR; PROTEIN P53; RAPAMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VQD 002; XL 147; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER GENETICS; CANCER GROWTH; CELL CYCLE ARREST; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; COLORECTAL CANCER; CPG ISLAND; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPIGENETICS; GENE AMPLIFICATION; GENE FREQUENCY; GENE INACTIVATION; GENE MUTATION; GENOMICS; HEREDITY; HUMAN; INTRACELLULAR SIGNALING; LUNG ADENOCARCINOMA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 79959974471     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.05.010     Document Type: Review

References (120)

1. E.T. Hawk, and B. Levin Colorectal cancer prevention J Clin Oncol 23 2005 378 391 (Pubitemid 46206885)
2. S.D. Markowitz, and M.M. Bertagnolli Molecular origins of cancer: Molecular basis of colorectal cancer N Engl J Med 361 2009 2449 2460
3. M.J. Waldner, and M.F. Neurath The molecular therapy of colorectal cancer Mol Aspects Med 31 2010 171 178
4. E.R. Fearon, and B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
5. M.S. Pino, and D.C. Chung The chromosomal instability pathway in colon cancer Gastroenterology 138 2010 2059 2072
6. C.R. Boland, and A. Goel Microsatellite instability in colorectal cancer Gastroenterology 138 2010 2073 2087 e3
7. Y. Ionov, M.A. Peinado, and S. Malkhosyan Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis Nature 363 1993 558 561 (Pubitemid 23186645)
8. Y. Yamada, L. Jackson-Grusby, and H. Linhart Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis Proc Natl Acad Sci U S A 102 2005 13580 13585 (Pubitemid 41420891)
9. D.J. Weisenberger, K.D. Siegmund, and M. Campan CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer Nat Genet 38 2006 787 793 (Pubitemid 43980599)
10. H. Tanaka, G. Deng, and K. Matsuzaki BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer Int J Cancer 118 2006 2765 2771 (Pubitemid 43673355)
11. L. Shen, M. Toyota, and Y. Kondo Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer Proc Natl Acad Sci U S A 104 2007 18654 18659 (Pubitemid 350210752)
12. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
13. S. Velho, C. Oliveira, and A. Ferreira The prevalence of PIK3CA mutations in gastric and colon cancer Eur J Cancer 41 2005 1649 1654 (Pubitemid 40981849)
14. L. Simi, N. Pratesi, and M. Vignoli High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer Am J Clin Pathol 130 2008 247 253
15. L.D. Wood, D.W. Parsons, and S. Jones The genomic landscapes of human breast and colorectal cancers Science 318 2007 1108 1113 (Pubitemid 350134889)
16. J.A. Engelman, J. Luo, and L.C. Cantley The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 2006 606 619 (Pubitemid 44100518)
17. D. Chantry, A. Vojtek, and A. Kashishian p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes J Biol Chem 272 1997 19236 19241 (Pubitemid 27337713)
18. P.K. Vogt PI3K p110beta: more tightly controlled or constitutively active? Mol Cell 41 2011 499 501
19. J. Yu, Y. Zhang, and J. McIlroy Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit Mol Cell Biol 18 1998 1379 1387 (Pubitemid 28100902)
20. D.D. Sarbassov, D.A. Guertin, and S.M. Ali Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101 (Pubitemid 40262113)
21. R. Zoncu, A. Efeyan, and D.M. Sabatini mTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cell Biol 12 2011 21 35
22. T. Maehama, and J.E. Dixon The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 273 1998 13375 13378 (Pubitemid 28268370)
23. L.S. Harrington, G.M. Findlay, and A. Gray The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins J Cell Biol 166 2004 213 223 (Pubitemid 38988774)
24. L. Bi, I. Okabe, and D.J. Bernard Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase J Biol Chem 274 1999 10963 10968
25. L. Bi, I. Okabe, and D.J. Bernard Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase Mamm Genome 13 2002 169 172 (Pubitemid 34185317)
26. J.J. Zhao, H. Cheng, and S. Jia The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation Proc Natl Acad Sci U S A 103 2006 16296 16300 (Pubitemid 44715190)
27. L.C. Foukas, M. Claret, and W. Pearce Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation Nature 441 2006 366 370 (Pubitemid 44050203)
28. Z.A. Knight, B. Gonzalez, and M.E. Feldman A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling Cell 125 2006 733 747
29. S. Gupta, A.R. Ramjaun, and P. Haiko Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice Cell 129 2007 957 968 (Pubitemid 46802703)
30. E. Ciraolo, M. Iezzi, and R. Marone Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development Sci Signal 1 2008 ra3
31. J. Guillermet-Guibert, K. Bjorklof, and A. Salpekar The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma Proc Natl Acad Sci U S A 105 2008 8292 8297 (Pubitemid 351904749)
32. S. Jia, Z. Liu, and S. Zhang Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis Nature 454 2008 776 779
33. T. Utermark, B.S. Schaffhausen, and T.M. Roberts The p110alpha isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation J Virol 81 2007 7069 7076 (Pubitemid 46986643)
34. P. Pu, C. Kang, and Z. Zhang Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo Technol Cancer Res Treat 5 2006 271 280 (Pubitemid 43946260)
35. S. Wee, D. Wiederschain, and S.M. Maira PTEN-deficient cancers depend on PIK3CB Proc Natl Acad Sci U S A 105 2008 13057 13062
36. H. Sheng, J. Shao, and C.M. Townsend Jr Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells Gut 52 2003 1472 1478 (Pubitemid 37176728)
37. A.J. Philp, I.G. Campbell, and C. Leet The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors Cancer Res 61 2001 7426 7429 (Pubitemid 32995029)
38. K. Khaleghpour, Y. Li, and D. Banville Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma Carcinogenesis 25 2004 241 248 (Pubitemid 38239808)
39. Y. Samuels, Z. Wang, and A. Bardelli High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554 (Pubitemid 38541907)
40. A. Agarwal, K. Das, and N. Lerner The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin Oncogene 24 2005 1021 1031 (Pubitemid 40313879)
41. D. Fang, D. Hawke, and Y. Zheng Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity J Biol Chem 282 2007 11221 11229 (Pubitemid 47100795)
42. X.C. He, T. Yin, and J.C. Grindley PTEN-deficient intestinal stem cells initiate intestinal polyposis Nat Genet 39 2007 189 198 (Pubitemid 46184349)
43. S.S. Ng, T. Mahmoudi, and E. Danenberg Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade J Biol Chem 284 2009 35308 35313
44. A. Lievre, H. Blons, and P. Laurent-Puig Oncogenic mutations as predictive factors in colorectal cancer Oncogene 29 2010 3033 3043
45. L. Barault, N. Veyrie, and V. Jooste Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers Int J Cancer 122 2008 2255 2259 (Pubitemid 351542328)
46. S. Velho, C. Moutinho, and L. Cirnes BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 8 2008 255
47. Y. Samuels, L.A. Diaz Jr, and O. Schmidt-Kittler Mutant PIK3CA promotes cell growth and invasion of human cancer cells Cancer Cell 7 2005 561 573 (Pubitemid 40799249)
48. T. Ikenoue, F. Kanai, and Y. Hikiba Functional analysis of PIK3CA gene mutations in human colorectal cancer Cancer Res 65 2005 4562 4567 (Pubitemid 40740791)
49. C.H. Huang, D. Mandelker, and O. Schmidt-Kittler The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations Science 318 2007 1744 1748 (Pubitemid 350274378)
50. N. Miled, Y. Yan, and W.C. Hon Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit Science 317 2007 239 242 (Pubitemid 47076198)
51. C. Chaussade, K. Cho, and C. Mawson Functional differences between two classes of oncogenic mutation in the PIK3CA gene Biochem Biophys Res Commun 381 2009 577 581
52. D. Mandelker, S.B. Gabelli, and O. Schmidt-Kittler A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane Proc Natl Acad Sci U S A 106 2009 16996 17001
53. L. Zhao, and P.K. Vogt Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms Proc Natl Acad Sci U S A 105 2008 2652 2657 (Pubitemid 351520568)
54. S. Kang, A. Denley, and B. Vanhaesebroeck Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase Proc Natl Acad Sci U S A 103 2006 1289 1294 (Pubitemid 43191158)
55. C. Benistant, H. Chapuis, and S. Roche A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells Oncogene 19 2000 5083 5090
56. B.S. Jaiswal, V. Janakiraman, and N.M. Kljavin Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation Cancer Cell 16 2009 463 474
57. C. Guo, J.F. Sah, and L. Beard The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers Genes Chromosomes Cancer 47 2008 939 946
58. Z.J. Wang, F. Taylor, and M. Churchman Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes Am J Pathol 153 1998 363 366 (Pubitemid 28373647)
59. A. Di Cristofano, B. Pesce, and C. Cordon-Cardo Pten is essential for embryonic development and tumour suppression Nat Genet 19 1998 348 355 (Pubitemid 28357906)
60. K. Okami, L. Wu, and G. Riggins Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors Cancer Res 58 1998 509 511 (Pubitemid 28087415)
61. J.G. Chang, Y.J. Chen, and L.I. Perng Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract Eur J Cancer 35 1999 647 651
62. X.P. Zhou, A. Loukola, and R. Salovaara PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers Am J Pathol 161 2002 439 447 (Pubitemid 36142153)
63. J. Tol, J.R. Dijkstra, and M. Klomp Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab Eur J Cancer 46 2010 1997 2009
64. G. Guanti, N. Resta, and C. Simone Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis Hum Mol Genet 9 2000 283 287 (Pubitemid 30052752)
65. K.H. Shin, Y.J. Park, and J.G. Park PTEN gene mutations in colorectal cancers displaying microsatellite instability Cancer Lett 174 2001 189 194 (Pubitemid 33022679)
66. I.M. Frayling, W.F. Bodmer, and I.P. Tomlinson Allele loss in colorectal cancer at the Cowden disease/juvenile polyposis locus on 10q Cancer Genet Cytogenet 97 1997 64 69 (Pubitemid 27318479)
67. A. Goel, C.N. Arnold, and D. Niedzwiecki Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers Cancer Res 64 2004 3014 3021 (Pubitemid 38581399)
68. A. Sartore-Bianchi, F. Di Nicolantonio, and M. Nichelatti Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer PLoS One 4 2009 e7287
69. M.J. Langlois, S. Bergeron, and G. Bernatchez The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression PLoS One 5 2010 e15742
70. Y. Saito, X. Swanson, and A.M. Mhashilkar Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo Gene Ther 10 2003 1961 1969 (Pubitemid 37337072)
71. H.K. Roy, B.F. Olusola, and D.L. Clemens AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis Carcinogenesis 23 2002 201 205 (Pubitemid 34213570)
72. J.D. Carpten, A.L. Faber, and C. Horn A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature 448 2007 439 444 (Pubitemid 47123510)
73. D.W. Parsons, T.L. Wang, and Y. Samuels Colorectal cancer: mutations in a signalling pathway Nature 436 2005 792 (Pubitemid 41160630)
74. S. Benvenuti, M. Frattini, and S. Arena PIK3CA cancer mutations display gender and tissue specificity patterns Hum Mutat 29 2008 284 288 (Pubitemid 351240601)
75. K. Nosho, T. Kawasaki, and M. Ohnishi PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations Neoplasia 10 2008 534 541 (Pubitemid 351770297)
76. M. Miyaki, T. Iijima, and T. Yamaguchi Mutations of the PIK3CA gene in hereditary colorectal cancers Int J Cancer 121 2007 1627 1630 (Pubitemid 47328725)
77. W. Li, T. Zhu, and K.L. Guan Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK J Biol Chem 279 2004 37398 37406 (Pubitemid 39195448)
78. E. Halilovic, Q.B. She, and Q. Ye PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling Cancer Res 70 2010 6804 6814
79. S. Ogino, K. Nosho, and G.J. Kirkner PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer J Clin Oncol 27 2009 1477 1484
80. J. Souglakos, J. Philips, and R. Wang Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer Br J Cancer 101 2009 465 472
81. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
82. A. Sartore-Bianchi, M. Martini, and F. Molinari PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 2009 1851 1857
83. E.J. Meuillet, N. Ihle, and A.F. Baker In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316 Oncol Res 14 2004 513 527 (Pubitemid 39551564)
84. P.C. Manegold, C. Paringer, and U. Kulka Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer Clin Cancer Res 14 2008 892 900 (Pubitemid 351231174)
85. C. Martin-Fernandez, J. Bales, and C. Hodgkinson Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs Mol Cancer Res 7 2009 955 965
86. G. Shapiro, E. Kwak, and J. Baselga Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors (abstr) J Clin Oncol 27 Suppl 2009 3500
87. J. Baselga, M.J. De Jonge, and J. Rodon A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors (abstr) J Clin Oncol 28 Suppl 2010 3003
88. D.D. Von Hoff, P. LoRusso, and R. Tibes A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors (abstr) J Clin Oncol 28 Suppl 2010 2541
89. S.T. Jou, N. Carpino, and Y. Takahashi Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex Mol Cell Biol 22 2002 8580 8591 (Pubitemid 35397173)
90. K. Okkenhaug, A. Bilancio, and G. Farjot Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice Science 297 2002 1031 1034 (Pubitemid 34856039)
91. R.R. Furman, J.C. Byrd, and I.W. Flinn Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies (abstr) J Clin Oncol 28 Suppl 2010 3032
92. K.E. O'Reilly, F. Rojo, and Q.B. She mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508 (Pubitemid 43259931)
93. Q.W. Fan, C.K. Cheng, and T.P. Nicolaides A dual phosphoinositide-3- kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma Cancer Res 67 2007 7960 7965 (Pubitemid 47395125)
94. V. Serra, B. Markman, and M. Scaltriti NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 68 2008 8022 8030
95. K.M. Vasudevan, D.A. Barbie, and M.A. Davies AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer Cancer Cell 16 2009 21 32
96. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484 (Pubitemid 43199434)
97. R. Bernardi, I. Guernah, and D. Jin PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR Nature 442 2006 779 785 (Pubitemid 44258904)
98. J.A. Engelman, L. Chen, and X. Tan Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 2008 1351 1356
99. Q.B. She, S. Chandarlapaty, and Q. Ye Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling PLoS One 3 2008 e3065
100. S. Semba, N. Itoh, and M. Ito The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells Clin Cancer Res 8 2002 1957 1963 (Pubitemid 34633759)
101. N. Itoh, S. Semba, and M. Ito Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma Cancer 94 2002 3127 3134 (Pubitemid 34670495)
102. Y. Sun, S. Zhao, and H. Tian Depletion of PI3K p85alpha induces cell cycle arrest and apoptosis in colorectal cancer cells Oncol Rep 22 2009 1435 1441
103. J.A. Engelman, and J. Settleman Acquired resistance to tyrosine kinase inhibitors during cancer therapy Curr Opin Genet Dev 18 2008 73 79 (Pubitemid 351694445)
104. M. Guix, A.C. Faber, and S.E. Wang Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins J Clin Invest 118 2008 2609 2619 (Pubitemid 351949788)
105. S. Wee, Z. Jagani, and K.X. Xiang PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers Cancer Res 69 2009 4286 4293
106. Bendell J LP, Kwak EL, et al. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: a first-in-human phase Ib study in patients with advanced solid tumors (abstr). In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; April 26, 2011; Orlando, FL.
107. T. Jun, O. Gjoerup, and T.M. Roberts Tangled webs: evidence of cross-talk between c-Raf-1 and Akt Sci STKE 1999 1999 PE1
108. Y.J. Zhang, X.Q. Tian, and D.F. Sun Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer Cancer Invest 27 2009 273 285
109. C. Xia, Q. Meng, and Z. Cao Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression J Cell Physiol 209 2006 56 66 (Pubitemid 44318667)
110. Q. Niu, C. Perruzzi, and D. Voskas Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1 Cancer Biol Ther 3 2004 402 405 (Pubitemid 41350872)
111. S. Wen, J. Stolarov, and M.P. Myers PTEN controls tumor-induced angiogenesis Proc Natl Acad Sci U S A 98 2001 4622 4627 (Pubitemid 32295026)
112. K. Hamada, T. Sasaki, and P.A. Koni The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis Genes Dev 19 2005 2054 2065 (Pubitemid 41247962)
113. J.F. Sun, T. Phung, and I. Shiojima Microvascular patterning is controlled by fine-tuning the Akt signal Proc Natl Acad Sci U S A 102 2005 128 133 (Pubitemid 40094440)
114. T.L. Yuan, H.S. Choi, and A. Matsui Class 1A PI3K regulates vessel integrity during development and tumorigenesis Proc Natl Acad Sci U S A 105 2008 9739 9744 (Pubitemid 352031370)
115. M. Graupera, J. Guillermet-Guibert, and L.C. Foukas Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration Nature 453 2008 662 666 (Pubitemid 351769296)
116. J.R. Garlich, P. De, and N. Dey A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res 68 2008 206 215 (Pubitemid 351380122)
117. C.R. Schnell, F. Stauffer, and P.R. Allegrini Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging Cancer Res 68 2008 6598 6607
118. S. Cascio, R. Ferla, and A. D'Andrea Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells J Cell Physiol 221 2009 189 194
119. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 9 2009 28 39
120. E.R. Zunder, Z.A. Knight, and B.T. Houseman Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha Cancer Cell 14 2008 180 192